Company News: BBT, WCC, WNS, ESRX, MHS, SFN, FFIV, RHI, IRDM

• BB&T Corp. (NYSE:BBT) reported Q2 EPS of $0.44, slightly above the Zacks Consensus Estimate of $0.42 per share. Revenues rose 7% year-over-year to $2.18 billion, beating the Zacks Consensus Estimate of $2.148 billion

• WESCO International, Inc. (NYSE:WCC) reported Q2 EPS of $1.00, surpassing the Zacks Consensus Estimate of $0.92 per share. Revenues for the quarter rose 21.1% year-over-year to $1.52 billion

• WNS Limited (NYSE:WNS) reported Q1 EPS of $0.22, beating the Zacks Consensus Estimate of $0.15 per share. Revenues for the quarter rose 9.5% year-over-year to $97.8 million, ahead of the Zacks Consensus Estimate of $94.0 million

• Express Scripts, Inc. (NASDAQ:ESRX) reported Q2 EPS of $0.71, in line with the Zacks Consensus Estimate. However, revenues for the quarter rose 0.6% year-over-year to $11.36 billion, higher than the Zacks Consensus Estimate of $11.322 billion

• Medco Health Solutions (NYSE:MHS) reported Q2 EPS of $0.96, marginally higher than the Zacks Consensus Estimate of $0.94 per share. Revenues for the quarter rose 3.5% year-over-year to $16.72 billion, lower than the Zacks Consensus Estimate of $17.086 billion

• Reacting to news that SFN Group Inc. (NYSE:SFN) will be acquired by the Dutch company Randstad Holding for $770 million, share prices of SFN rose 51.08% a day to close at $13.93

• Express Scripts Inc. (NASDAQ:ESRX) announced its decision to buy pharmacy-benefits manager Medco Health Solutions Inc (NYSE:MHS) in a deal valued at $29.1 billion in cash and stock

• Shares of F5 Networks Inc. (NASDAQ:FFIV) fell 11.28% a day after the software company posted its earnings results for the third quarter that came in below expectations

• Analysts at Robert W. Baird upgraded Robert Half Intl Inc. (NYSE:RHI) to an “Outperform” rating from a “Neutral” rating setting a target price of $35.00 on the shares of the company

• Morgan Keegan analysts initiated coverage on shares of Iridium Communications (NASDAQ:IRDM) with an “Outperform” rating and with a target price of $12.00

EXPRESS SCRIPTS (ESRX): Free Stock Analysis Report

About Zacks Investment Research 1767 Articles

Zacks Investment Research is one of the most highly regarded firms in the investment industry. In 1978 Zacks originated the concept of utilizing earnings estimates revisions to make profitable investment decisions. Zacks offers multiple investment products and services to help investors achieve superior returns.

Visit: Zacks.com

Be the first to comment

Leave a Reply

Your email address will not be published.


*